There is decreased risk for CV events and mortality in patients with cardiac autonomic neuropathy that receive intensive glycemic treatment.

New 10-year data from the DANAMI-3-PRIMULTI trial show long-term benefits of complete revascularization for patients with STEMI and multivessel disease compared with treatment of the infarct-related ...